Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

A. Ganser | J. Johansson | R. Fanin | N. Kröger | C. Craddock | H. Tilly | M. Labopin | P. Chevallier | I. Yakoub-Agha | D. Blaise | A. Nagler | M. Mohty | J. Byrne | P. Rohrlich | M. Aljurf | P. Dreger | E. Deconinck | A. Risitano | M. Ladetto | H. Greinix | X. Leleu | J. Bay | S. Santarone | G. Kobbe | J. Pérez-Simón | A. Bazarbachi | O. Hermine | J. Cornelissen | Depei Wu | G. Socié | S. Lenhoff | A. Neubauer | S. Apte | P. Reményi | N. Milpied | R. Vrhovac | M. Bornhäuser | W. Bethge | E. Faber | G. Damaj | K. Halaburda | A. Rambaldi | T. Gedde-Dahl | P. Corradini | M. Collin | P. Žák | H. Ozdogu | B. Savani | A. Tbakhi | M. Rubio | M. Stelljes | C. Selleri | M. Petrini | J. Malfuson | A. Spyridonidis | M. Klammer | A. Ho | V. Gandemer | B. Lioure | J. Díez-Martín | P. Bernasconi | M. Arat | I. Karadoğan | D. Beelen | S. Martin | A. Lange | E. Meijer | A. Brecht | V. Potter | M. Rovira | K. Orchard | Y. Koç | J. Tischer | D. Guyotat | H. Martin | C. Bulabois | K. Schäfer-Eckart | N. Fegueux | J. Clausen | L. Müller | F. Benedetti | S. Giebel | A. Olivieri | A. Huynh | D. Caballero | R. Protheroe | T. Heinicke | Mercedes Colorado Araujo | N. Mordini | Małgorzata Sobczyk-Kruszelnicka | Maija Itäla-Remes | Sonja Patrice Andreas Gandhi Yener Arnold Matthew Ibrahi Martin Chevallier Neubauer Damaj Koc Ganser | C. Isaksson | J. L. B. López | T. Gedde‐Dahl | Juan Pio Torres Carrete | Murawski Niels | J. L. Lorenzo | M. Zahrani | C. Llamas | J. R. Santasusana | A. Kaare | M. C. Araujo | K. Schäfer‐Eckart | Y. Koc | M. Sobczyk-Kruszelnicka

[1]  J. Esteve,et al.  Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients , 2020, Bone Marrow Transplantation.

[2]  A. Nagler,et al.  Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation , 2019, Clinical hematology international.

[3]  H. Deeg,et al.  Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Nagler,et al.  Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation , 2019, Clinical hematology international.

[5]  H. Eich,et al.  Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. , 2018, The Lancet. Haematology.

[6]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[7]  P. Thall,et al.  Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients , 2016, Bone Marrow Transplantation.

[8]  B. Andersson,et al.  Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? , 2016, Bone Marrow Transplantation.

[9]  L. Vidal,et al.  Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis , 2016, Bone Marrow Transplantation.

[10]  P. Chiusolo,et al.  Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[11]  M. Labopin,et al.  Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. , 2015, The Lancet. Haematology.

[12]  C. Craddock,et al.  Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT , 2015, Bone Marrow Transplantation.

[13]  M. Labopin,et al.  Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial , 2015, Cancer.

[14]  J. Esteve,et al.  Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 2014, Cancer.

[15]  J. Cortes,et al.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. , 2013, Blood.

[16]  J. Dipersio,et al.  Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. , 2013, Blood.

[17]  Yu Wang,et al.  Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study , 2013, International Journal of Hematology.

[18]  M. Labopin,et al.  Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Min,et al.  Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Tu,et al.  Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study , 2013, Journal of Hematology & Oncology.

[21]  W. Hiddemann,et al.  Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.

[22]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  H. Deeg,et al.  Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. , 2001, Blood.

[25]  V. Budach,et al.  Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  J P Klein,et al.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.

[27]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[28]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[29]  A. Leiper.  Late effects of total body irradiation. , 1995, Archives of disease in childhood.

[30]  P. Hougaard,et al.  Frailty models for survival data , 1995, Lifetime data analysis.

[31]  P. Ljungman,et al.  A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. , 1994, Blood.

[32]  D. Blaise,et al.  Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments] , 1992 .